“Notable” from “Over there”...
PCR Testing Scandal: Yes, We Were Duped.
It is the keystone block of the entire ‘public health’ crisis narrative. Despite many independent experts and journalists raising the alarm last year, this issue was purposely avoided by the mainstream media, as well as both U.S. and European federal health officials and other supposed ‘experts’ at the WHO. Were they really unaware of the fatal flaw of using high cycle counts (CT) for PCR tests – readings that would certainly produce an astronomical number of false positives for COVID-19? Exposing the medical fraud and pseudoscience at the center of the entire ‘global pandemic’….
Curative offers a PCR test using spit rather than swabs from the back of your nasal cavity. Initially only authorized for use on symptomatic patients, the company has requested the U.S. Food and Drug Administration expand its authorization for use on asymptomatic individuals.
According to company data, the spit test accurately identifies about 90% of positive cases when compared against a nasopharyngeal PCR test set to 35 cycle threshold (CT).
According to the FDA, that comparative CT is too low, and will produce too many false negatives. This, despite the scientific consensus, which states anything over 35 CTs is scientifically unjustifiable as it produces enormous amounts of false positives.
According to an April 2020 study, a CT of 17 must be used to obtain 100% confirmed real positives. Above 17 cycles, accuracy drops dramatically. At 33 cycles, the false positive rate is 80%. Beyond 34 cycles, the false positive rate reaches 100%.
Because the PCR test cannot discern between live virus and dead, noninfectious viral debris, the timing of the test is important. Recent research shows the median time from symptom onset to viral clearance confirmed by viral culture is seven days, whereas the PCR test continues to detect nonviable (noninfectious) SARS-CoV-2 for a median of 34 days.
For several months, experts have highlighted the true cause behind the COVID-19 pandemic, namely the incorrect use of PCR tests set at a ridiculously high cycle count (CT), which falsely labels healthy people as “COVID-19 cases.” In reality, the PCR test is not a proper diagnostic test, although it has been promoted as such.
An important question that demands an answer is whether the experts at our federal health agencies and the World Health Organization were really too ignorant to understand the implications of using this test at excessive CT, or whether it was done on purpose to create the illusion of a dangerous, out-of-control pandemic.
Regardless, those in charge need to be held accountable, which is precisely what the German Corona Extra-Parliamentary Inquiry Committee (Außerparlamentarischer Corona Untersuchungsausschuss, or ACU), intends to do.
They’re in the process of launching an international class-action lawsuit against those responsible for using fraudulent testing to engineer the appearance of a dangerous pandemic in order to implement economically devastating lockdowns around the world. I wrote about this in “Coronavirus Fraud Scandal — The Biggest Fight Has Just Begun” and “German Lawyers Initiate Class-Action Coronavirus Litigation.”
FDA demands higher false positives
An interesting case detailed in a Jan. 21 Buzzfeed article that raises those same questions in regard to the U.S. Food and Drug Administration is its recent spat with Curative, a California testing company that got its start in Jan. 2020. It has since risen to become one of the largest COVID-19 test providers in the U.S.
Curative’s most popular PCR test differs from other providers in that it uses spit swabbed from the patient’s tongue, cheek and mouth rather than from the back of the nasal cavity.
In April 2020, the FDA issued an accelerated emergency use authorization for the Curative spit test, but only for patients who had been symptomatic within the two weeks prior to taking the test, as the data available at that time showed it failed to catch asymptomatic “cases.”
However, the test was subsequently used off-label on individuals without symptoms anyway, and the company has been urging the FDA to expand its authorization to include asymptomatic individuals based on newer data.